Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

851 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.
Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, Nadel H, Randall RL, Deffenbaugh C, Nagarajan R, Brennan B, Letson GD, Teot LA, Goorin A, Baumhoer D, Kager L, Werner M, Lau CC, Sundby Hall K, Gelderblom H, Meyers P, Gorlick R, Windhager R, Helmke K, Eriksson M, Hoogerbrugge PM, Schomberg P, Tunn PU, Kühne T, Jürgens H, van den Berg H, Böhling T, Picton S, Renard M, Reichardt P, Gerss J, Butterfass-Bahloul T, Morris C, Hogendoorn PC, Seddon B, Calaminus G, Michelagnoli M, Dhooge C, Sydes MR, Bernstein M; EURAMOS-1 investigators. Bielack SS, et al. Among authors: gelderblom h. J Clin Oncol. 2015 Jul 10;33(20):2279-87. doi: 10.1200/JCO.2014.60.0734. Epub 2015 Jun 1. J Clin Oncol. 2015. PMID: 26033801 Free PMC article. Clinical Trial.
Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases.
van Iersel LB, Hoekman EJ, Gelderblom H, Vahrmeijer AL, van Persijn van Meerten EL, Tijl FG, Hartgrink HH, Kuppen PJ, Nortier JW, Tollenaar RA, van de Velde CJ. van Iersel LB, et al. Among authors: gelderblom h. Ann Surg Oncol. 2008 Jul;15(7):1891-8. doi: 10.1245/s10434-008-9881-6. Epub 2008 May 10. Ann Surg Oncol. 2008. PMID: 18470571 Free PMC article. Clinical Trial.
Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA, Steeghs N, Verweij J, Bloem JL, Christensen O, van Doorn L, Ouwerkerk J, de Jonge MJ, Nortier JW, Kraetzschmar J, Rajagopalan P, Gelderblom H. Eskens FA, et al. Among authors: gelderblom h. J Clin Oncol. 2009 Sep 1;27(25):4169-76. doi: 10.1200/JCO.2008.18.8193. Epub 2009 Jul 27. J Clin Oncol. 2009. PMID: 19636022 Clinical Trial.
Prognostic factors in pulmonary metastasized high-grade osteosarcoma.
Buddingh EP, Anninga JK, Versteegh MI, Taminiau AH, Egeler RM, van Rijswijk CS, Hogendoorn PC, Lankester AC, Gelderblom H. Buddingh EP, et al. Among authors: gelderblom h. Pediatr Blood Cancer. 2010 Feb;54(2):216-21. doi: 10.1002/pbc.22293. Pediatr Blood Cancer. 2010. PMID: 19890902
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Hogendoorn PC; ESMO/EUROBONET Working Group; Athanasou N, Bielack S, De Alava E, Dei Tos AP, Ferrari S, Gelderblom H, Grimer R, Hall KS, Hassan B, Hogendoorn PC, Jurgens H, Paulussen M, Rozeman L, Taminiau AH, Whelan J, Vanel D. Hogendoorn PC, et al. Among authors: gelderblom h. Ann Oncol. 2010 May;21 Suppl 5:v204-13. doi: 10.1093/annonc/mdq223. Ann Oncol. 2010. PMID: 20555083 Free article. No abstract available.
First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study.
Kroep JR, Ouali M, Gelderblom H, Le Cesne A, Dekker TJA, Van Glabbeke M, Hogendoorn PCW, Hohenberger P. Kroep JR, et al. Among authors: gelderblom h. Ann Oncol. 2011 Jan;22(1):207-214. doi: 10.1093/annonc/mdq338. Epub 2010 Jul 23. Ann Oncol. 2011. PMID: 20656792 Free PMC article.
Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?
Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AH, Hogendoorn PC, Egeler RM. Anninga JK, et al. Among authors: gelderblom h. Eur J Cancer. 2011 Nov;47(16):2431-45. doi: 10.1016/j.ejca.2011.05.030. Epub 2011 Jun 22. Eur J Cancer. 2011. PMID: 21703851 Review.
Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials.
Whelan JS, Jinks RC, McTiernan A, Sydes MR, Hook JM, Trani L, Uscinska B, Bramwell V, Lewis IJ, Nooij MA, van Glabbeke M, Grimer RJ, Hogendoorn PC, Taminiau AH, Gelderblom H. Whelan JS, et al. Among authors: gelderblom h. Ann Oncol. 2012 Jun;23(6):1607-16. doi: 10.1093/annonc/mdr491. Epub 2011 Oct 19. Ann Oncol. 2012. PMID: 22015453 Free PMC article.
851 results